Yuto Sunaga

Yuto Sunaga

Auto-generated profile, based on publicly available information

Yuto Sunaga

Department of Pediatrics, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
NKNobuyuki Katsumata
Nobuyuki Katsumata
DHDaisuke Harama
Daisuke Harama
TTTakako Toda
Takako Toda
YSYuto Sunaga
Yuto Sunaga
MYMasashi Yoshizawa
Masashi Yoshizawa
TITakeshi Inukai
Takeshi Inukai
BackgroundKawasaki disease is suspected to be triggered by previous infection. The prevention measures for COVID-19 have reportedly reduced transmission of certain infectious diseases. Under these circumstances, the prevention measures for COVID-19 may reduce the incidence of Kawasaki disease.MethodWe conducted a retrospective study using registration datasets of patients with Kawasaki disease who were diagnosed in all 11 in-patient pediatric facilities in Yamanashi prefecture. The eligible cases were 595 cases that were diagnosed before the COVID-19 pandemic (from January 2015 to February 2020) and 38 cases that were diagnosed during the COVID-19 pandemic (from March to November 2020). Incidence of several infectious disease were evaluated using data from the Infectious Disease Weekly Report conducted by the National Institute of Infectious Diseases.ResultsEpidemics of various infectious diseases generally remained at low levels during the first nine months (March to November 2020) of the COVID-19 pandemic. Moreover, the incidence of COVID-19 was 50–80 times lower than the incidence in European countries and the United States. The total number of 38 cases with Kawasaki disease for the nine months during the COVID-19 pandemic was 46.3% (-3.5 standard deviation (SD)) of the average (82.0 (SD, 12.7)) for the corresponding nine months of the previous five years. None of the 38 cases was determined to be triggered by COVID-19 based on their medical histories and negative results of severe acute respiratory syndrome coronavirus 2 testing at admission.ConclusionThese observations provide a new epidemiological evidence for the notion that Kawasaki disease is triggered by major infectious diseases in children.

20 June 2025 in Pediatric Research
Verified
Journal Article
Open access
PDF file
YSYuto Sunaga
Yuto Sunaga
YHYohei Hasebe
Yohei Hasebe
NKNatsumi Kikuchi
Natsumi Kikuchi
MYMasashi Yoshizawa
Masashi Yoshizawa
YKYosuke Kono
Yosuke Kono
TITakeshi Inukai
Takeshi Inukai
Background: To clarify the clinical characteristics associated with coronary artery abnormality (CAA) in the acute phase of Kawasaki disease (KD) cases, we performed a cluster analysis. Methods: A retrospective cohort study of 103 KD cases that developed CAA (maximum Z-score for any coronary arteries >2.5) within 30 days after disease onset was conducted among 726 consecutive KD cases. The hierarchical cluster analysis was performed based on 20 continuous variables before treatment. Results: 101 out of 103 cases were clustered into 4 subgroups. Cluster 1 was a younger group characterized by leukocytosis and elevated serum triglyceride levels with frequent coronary artery dilation before treatment and good initial treatment responses. Cluster 2 was a younger group characterized by anemia and lower serum albumin and total cholesterol levels. Cluster 3 was an older group with frequent coronary artery dilation before treatment. Cluster 4 was an older group characterized by elevated serum aspartate aminotransferase, alanine aminotransferase, and total bilirubin levels, with poor treatment response and the lowest incidence of coronary artery dilatation before treatment. Conclusion: We identified four subgroups with distinct features, suggesting different backgrounds for CAA development. Consideration of possible heterogeneity might be helpful for a better understanding of the pathophysiology and better treatment strategies. Impact: To investigate possible heterogeneity in Kawasaki disease (KD) cases that developed coronary artery abnormality (CAA) in the acute phase and to evaluate associated clinical characteristics, we performed a cluster analysis in KD cases that developed CAA in the acute phase. Hierarchical cluster analysis in KD cases that developed CAA within 30 days after disease onset, based on clinical data before treatment, identified four subgroups with distinct features, suggesting different backgrounds for CAA development. Cluster analysis might be helpful for a better understanding of the pathophysiology and better treatment strategies in KD cases at high risk for developing CAAs.

15 March 2023 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
YSYuto Sunaga
Yuto Sunaga
AWAtsushi Watanabe
Atsushi Watanabe
NKNobuyuki Katsumata
Nobuyuki Katsumata
TTTakako Toda
Takako Toda
MYMasashi Yoshizawa
Masashi Yoshizawa
TITakeshi Inukai
Takeshi Inukai

4 June 2026 in Pediatric Cardiology
Verified
Journal Article
Open access
YSYuto Sunaga
Yuto Sunaga
YHYohei Hasebe
Yohei Hasebe
MYMasashi Yoshizawa
Masashi Yoshizawa
YKYosuke Kono
Yosuke Kono
KKKeiichi Koizumi
Keiichi Koizumi
TITakeshi Inukai
Takeshi Inukai
For high-dose intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD), individualized selection of second-line therapy according to clinical subgroups could be useful to prevent progression of coronary artery abnormalities. We retrospectively analyzed IVIG-resistant KD patients aged ≥ 1 year treated with additional IVIG ( n = 70) or infliximab (IFX) ( n = 54) by applying clustering approaches. Consistent with previous studies, fever resolved significantly faster in the IFX group (median 72 h) than in the second IVIG group (96 h; p = 0.02). However, the incidence of residual coronary artery abnormalities (Z-score ≥ 2.5) at 30 days, 6 months, and 1 year did not differ significantly between the two treatment groups. In the first clustering approach, which was based on ten baseline laboratory variables, the two identified subgroups were not clearly associated with differential treatment responses. In a secondary clustering analysis using four treatment-associated factors (serum sodium, C-reactive protein, total cholesterol, and HDL cholesterol), the three identified stable subgroups were associated with differential treatment responses. Among the three clusters, Cluster 1 showed a favorable response to second IVIG (resistance rate, 7/36 [19.4%]) but a relatively poor response to IFX (12/28 [42.9%]). In contrast, Clusters 2 and 3, characterized by dyslipidemia with decreased total cholesterol and HDL cholesterol levels, were resistant to second IVIG (7/17 [41.2%] and 8/17 [47.1%], respectively) but relatively sensitive to IFX (0/7 [0%] and 6/19 [31.6%], respectively). These findings suggest that IFX may be an effective second-line therapy for IVIG-resistant KD patients with severe dyslipidemia, whereas additional IVIG may remain beneficial for those without dyslipidemia.

24 May 2022 in Research Square
Verified
Preprint
Open access
PDF file
YSYuto Sunaga
Yuto Sunaga
AWAtsushi Watanabe
Atsushi Watanabe
NKNobuyuki Katsumata
Nobuyuki Katsumata
TTTakako Toda
Takako Toda
MYMasashi Yoshizawa
Masashi Yoshizawa
TITakeshi Inukai
Takeshi Inukai
In Kawasaki disease (KD), accurate prediction of intravenous immunoglobulin (IVIG) resistance is crucial to reduce a risk for developing coronary artery lesions. To establish a simple and accurate scoring model predicting IVIG resistance, we conducted a retrospective cohort study of 996 KD patients that were diagnosed at 11 facilities for 10 years, in which 108 cases (23.5%) were resistant to initial IVIG treatment. We performed machine learning with random forest model using 30 clinical variables at diagnosis in 796 and 200 cases for training and test datasets, respectively. Random forest model accurately predicted IVIG resistance (AUC: 0.75, sensitivity: 0.54, specificity: 0.80). Next, using top five influential features (days of illness at initial therapy, serum levels of C-reactive protein, sodium, total bilirubin, and total cholesterol) in the random forest model, we designed a simple scoring system. In spite of its simplicity, the scoring system predicted IVIG resistance (AUC: 0.73, sensitivity: 0.55, specificity: 0.83) as accurately as the random forest model itself. Moreover, accuracy of our scoring system with five clinical features was almost identical to that of Gunma score with seven clinical features (AUC: 0.73, sensitivity: 0.53, specificity: 0.83), a well-known logistic regression scoring model, and superior to that of two widely used scores (Kurume score: 0.67, 0.46 and 0.76, respectively, and Osaka score: 0.69, 0.33 and 0.84, respectively). Conclusions: Our simple scoring system based on the findings in machine learning, as well as machine learning itself, seems to be useful to accurately predict IVIG resistance in KD patients.